Any possibility that the Michael J Fox Foundation (MJFF) is keeping a watchful eye on the -201 and -202 trials? The underlying pathology for Parkinsons and MSA is similar, so is it unreasonable to think that the MJFF is waiting for the -201 results early next year, and if successful, make a sizable contribution for a -202 style trial, or a confirmatory trial so that if or when ATH434 is approved by the FDA for early stage MSA, then Alterity can follow up fairly quickly to get ATH434 approved for Parkinsons?
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-157
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.62M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $886 | 275.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 48 | 56368671 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 125986200 | 26 |
View Market Depth
| Last trade - 11.34am 30/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |